City Therapeutics Prices IPO at $18 Per Share, Raising $200 Million

City Therapeutics priced its initial public offering at $18 per share, a deal that raises about $200 million. The pricing concludes the company's marketing effort to investors and clears the way for its shares to begin trading on a public exchange.

The offering lands in a selective market for new biotech listings, where investors have tended to favor issuers with late-stage programs and a clear path to funding key milestones. Demand for a deal of this size suggests the company drew interest from institutional buyers during its roadshow.

Proceeds from a listing of this size are commonly directed toward research and development, clinical programs and general corporate needs, giving a newly public drug developer room to fund milestones without returning to private investors. How the company allocates that capital will shape its timeline for reaching key data points.

The first days of trading will draw close attention, since early performance often sets the tone for other private companies weighing listings. Bankers and investors will watch whether the shares hold near the offer price as a gauge of appetite for the sector.